Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Archivum Immunologiae et Therapiae Experimentalis

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 15761376
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Life Cycle of P53: A Key Target in Drug Development

  2005cited by this paper
• Current strategies in tumor-targeting

  2005cited by this paper
• Growth Factors, Receptors, and Kinases: Their Exploration to Target Cancer

  2005cited by this paper
• Amplification of anticancer drug-induced DNA damage and apoptosis by DNA-binding compounds.

  2004cited by this paper
• Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein.

  2004cited by this paper
• Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth

  2004cited by this paper
• Update on the proteasome inhibitor bortezomib in hematologic malignancies.

  2004cited by this paper
• Drug delivery of oligonucleotides by peptides.

  2004cited by this paper
• Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.

  2004cited by this paper
• Caspases and cancer: mechanisms of inactivation and new treatment modalities.

  2004cited by this paper
• Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions

  2004cited by this paper
• NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.

  2004cited by this paper
• The Critical Features and the Mechanism of Inhibition of a Kinase Interaction Motif-based Peptide Inhibitor of JNK*

  2004cited by this paper
• Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation".

  2004cited by this paper
• Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.

  2004cited by this paper
• Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix

  2004cited by this paper
• Cancer: An inflammatory link

  2004cited by this paper
• Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development.

  2004cited by this paper
• The proteasome: a suitable antineoplastic target

  2004cited by this paper
• Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

  2004cited by this paper
• Progress in Clinical Neurosciences: Pharmacotherapies for the Secondar Prevention of Stroke

  2004cited by this paper
• Development of the Proteasome Inhibitor Velcade™ (Bortezomib)

  2004cited by this paper
• The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.

  2004cited by this paper
• Inflammatory response, reactive oxygen species, programmed (necrotic-like and apoptotic) cell death and cancer.

  2004cited by this paper
• Helical β-Peptide Inhibitors of the p53-hDM2 Interaction

  2004cited by this paper
• Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications.

  2004cited by this paper
• Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.

  2004cited by this paper
• Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins.

  2004cited by this paper
• Suppression of tumor growth and metastasis by a VEGFR‐1 antagonizing peptide identified from a phage display library

  2004cited by this paper
• Cell death: critical control points.

  2004cited by this paper
• Review Cell Death: Critical Control Points Another Line of Evidence for the Importance of Caspases in Cell Death Came From

  2004cited by this paper
• Proteasome inhibitor PS‐341 induces growth arrest and apoptosis of non‐small cell lung cancer cells via the JNK/c‐Jun/AP‐1 signaling

  2004cited by this paper
• Induction of apoptosis in cultured endothelial cells by a cadherin antagonist peptide: involvement of fibroblast growth factor receptor-mediated signalling.

  2004cited by this paper
• Proteasome inhibitor PS‐341 down‐regulates prostate‐specific antigen (PSA) and induces growth arrest and apoptosis of androgen‐dependent human prostate cancer LNCaP cells

  2004cited by this paper
• Somatostatin Receptor Targeting for Tumor Imaging and Therapy

  2004cited by this paper
• Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells

  2004cited by this paper
• Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.

  2003cited by this paper
• Selective targeting of cancer cells using synthetic peptides.

  2003cited by this paper
• Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site

  2003cited by this paper
• Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells

  2003cited by this paper
• Targets in Apoptosis Signaling

  2003cited by this paper
• Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide

  2003cited by this paper
• Targeting tumor cells.

  2003cited by this paper
• Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-κB independent mechanisms

  2003cited by this paper
• Targeting Bcl-2 Related Proteins in Cancer Therapy

  2003cited by this paper
• Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis.

  2003cited by this paper
• Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide.

  2003cited by this paper
• Viral modulation of cell death by inhibition of caspases.

  2003cited by this paper
• Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design.

  2003cited by this paper
• Concise and enantioselective synthesis of Fmoc-Pmp(But)2-OH and design of potent Pmp-containing Grb2-SH2 domain antagonists.

  2003cited by this paper
• Phage display selection and evaluation of cancer drug targets.

  2003cited by this paper
• Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex.

  2003cited by this paper
• Innovations in oligonucleotide drug delivery

  2003cited by this paper
• Antiangiogenic therapy: more promise and, yet again, more questions.

  2003cited by this paper
• Development and characterization of potent and specific peptide inhibitors of p60c-src protein tyrosine kinase using pseudosubstrate-based inhibitor design approach.

  2003cited by this paper
• Restoring p53-Dependent Tumor Suppression

  2003cited by this paper
• Targets in apoptosis signaling: promise of selective anticancer therapy.

  2003cited by this paper
• Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process

  2003cited by this paper
• Cell-penetrating Peptides

  2003cited by this paper
• Sequence-specific Peptide Aptamers, Interacting with the Intracellular Domain of the Epidermal Growth Factor Receptor, Interfere with Stat3 Activation and Inhibit the Growth of Tumor Cells*

  2003cited by this paper
• A targeted approach for antiangiogenic therapy of metastatic human colon cancer.

  2003cited by this paper
• Poxviruses and apoptosis: a time to die.

  2002cited by this paper
• The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules.

  2002cited by this paper
• Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

  2002cited by this paper
• Peptidomimetics and angiogenesis.

  2002cited by this paper
• Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis.

  2002cited by this paper
• Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling.

  2002cited by this paper
• Development of a Potent Bcl-xL Antagonist Based on α-Helix Mimicry

  2002cited by this paper
• Identification of the Critical Features of a Small Peptide Inhibitor of JNK Activity*

  2002cited by this paper
• A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants

  2002cited by this paper
• Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity.

  2002cited by this paper
• Role of angiogenesis in tumor growth and metastasis.

  2002cited by this paper
• Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

  2002cited by this paper
• Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L).

  2002cited by this paper
• Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry.

  2002cited by this paper
• Smac agonists sensitize for Apo 2 L / TRAILor anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

  2002cited by this paper
• Cellular import mediated by nuclear localization signal Peptide sequences.

  2002cited by this paper
• Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo.

  2001cited by this paper
• Human antibodies as next generation therapeutics.

  2001cited by this paper
• Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action.

  2001cited by this paper
• Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells

  2001cited by this paper
• Drug-targeting strategies in cancer therapy.

  2001cited by this paper
• Cell-Permeable Peptide Inhibitors of JNK: Novel Blockers of β-Cell Death

  2001cited by this paper
• Cytochrome c is rapidly extruded from apoptotic cells and detectable in serum of anticancer-drug treated tumor patients.

  2001cited by this paper
• Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death.

  2001cited by this paper
• Synthetic peptides and non-peptidic molecules as probes of structure and function of Bcl-2 family proteins and modulators of apoptosis

  2001cited by this paper
• Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors.

  2001cited by this paper
• Human antibodies as next generation therapeutics.

  2001cited by this paper
• Bcl-2 family proteins as targets for anticancer drug design

  2000cited by this paper
• Nuclear Transport of Oligonucleotides in HepG2-cells Mediated by Protamine Sulfate and Negatively Charged Liposomes

  2000cited by this paper
• Structural and biochemical basis of apoptotic activation by Smac/DIABLO

  2000cited by this paper
• Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Structural basis of IAP recognition by Smac/DIABLO

  2000cited by this paper
• Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells.

  2000cited by this paper
• Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes.

  2000cited by this paper
• Rationale for Bcl‐XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies

  2000cited by this paper
• p53 and human cancer: the first ten thousand mutations.

  2000cited by this paper
• Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain

  1999cited by this paper
• Bak BH3 Peptides Antagonize Bcl-xL Function and Induce Apoptosis through Cytochrome c-independent Activation of Caspases*

  1999cited by this paper

• Advances in chemically modified HSA as a multifunctional carrier for transforming cancer therapy regimens.

  2025cites this paper
• Insights into protein–DNA interactions from hydrogen bond energy‐based comparative protein–ligand analyses

  2022cites this paper
• Candidone inhibits migration and invasion, and induces apoptosis in HepG2 cells.

  2021cites this paper
• Downregulation of hexokinase 2 improves radiosensitivity of breast cancer

  2019cites this paper
• In Vitro Characterization and Evaluation of Silver Nanoparticles Cytotoxicity on Human “Liver and Breast” Cancer Cells Versus Normal Melanocytes

  2019cites this paper
• Developments of Cyanobacteria for Nano-Marine Drugs: Relevance of Nanoformulations in Cancer Therapies

  2018cites this paper
• Chapter 2 Fungal-Derived Nanoparticles as Novel Antimicrobial and Anticancer Agents

  2017cites this paper
• Fungal-Derived Nanoparticles as Novel Antimicrobial and Anticancer Agents

  2016cites this paper
• Recognition Dynamics of p53 and MDM2: Implications for Peptide Design.

  2016cites this paper
• Heptaphylline induces apoptosis in human colon adenocarcinoma cells through bid and Akt/NF-κB (p65) pathways.

  2015cites this paper
• Reversal of Chemoresistance in Human Lung Cancer Cell Line A549/Taxol by Synthetic Second Mitochondria-Derived Activator of Caspase Peptide.

  2015cites this paper
• Development of biologics for use in translational medicine

  2015cites this paper
• ACPP: A Web Server for Prediction and Design of Anti-cancer Peptides

  2014cites this paper
• Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides

  2013cites this paper
• Potent anticancer activity of cystine-based dipeptides and their interaction with serum albumins

  2013cites this paper
• Low density lipoproteins mediated nanoplatforms for cancer targeting

  2013cites this paper
• On the selectivity and efficacy of defense peptides with respect to cancer cells

  2013cites this paper
• Mitoptosis, a Novel Mitochondrial Death Mechanism Leading Predominantly to Activation of Autophagy

  2012cites this paper
• Advances in methods for therapeutic peptide discovery, design and development.

  2011cites this paper
• Mass Transport via Cellular Barriers and Endocytosis

  2011cites this paper
• Promises of apoptosis-inducing peptides in cancer therapeutics.

  2011cites this paper
• The therapeutic potential of the filarial nematode‐derived immunodulator, ES‐62 in inflammatory disease

  2010cites this paper
• Development of peptides as potential drugs for cancer therapy.

  2010cites this paper
• Effect of RasGAP N2 fragment-derived peptide on tumor growth in mice.

  2009cites this paper
• Alleviating the ischemia-reperfusion injury of donor liver by transfection of exogenous hTERT genes.

  2009cites this paper
• Bcl-XL protein is markedly decreased in UVB-irradiated basal cell carcinoma cell lines through proteasome-mediated degradation.

  2009cites this paper
• Abrus abrin derived peptides induce apoptosis by targeting mitochondria in HeLa cells

  2009cites this paper
• [Peptides: a new class of anticancer drugs].

  2009cites this paper
• Targeting tumors with peptides from natural sources.

  2008cites this paper
• Ruthenium polypyridyl peptide conjugates: membrane permeable probes for cellular imaging.

  2008cites this paper
• Antitumor and proapoptotic effect of Abrus agglutinin derived peptide in Dalton's lymphoma tumor model.

  2008cites this paper
• Targeting synuclein-gamma to counteract drug resistance in cancer.

  2008cites this paper
• Peptides and Peptidomimetics as Cancer Therapy Sensitizing Agents

  2008cites this paper
• Targeting synuclein-γ to counteract drug resistance in cancer

  2008cites this paper
• Nanovehicular intracellular delivery systems.

  2008cites this paper
• Organelle-targeted delivery of biological macromolecules using the protein transduction domain: potential applications for Peptide aptamer delivery into the nucleus.

  2008cites this paper
• Selected technologies to control genes and their products for experimental and clinical purposes

  2007cites this paper
• Cytotoxic effects of intra and extracellular zinc chelation on human breast cancer cells.

  2007cites this paper
• Inhibition of heat shock protein 27-mediated resistance to DNA damaging agents by a novel PKC delta-V5 heptapeptide.

  2007cites this paper
• Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide.

  2007cites this paper
• 5 – The cutting edge: apoptosis and therapeutic opportunity

  2007cites this paper
• Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy.

  2007influential citation
• Monoclonal and bispecific antibodies as novel therapeutics

  2006cites this paper
• Proteasome Inhibitors Potentiate Etoposide-Induced Cell Death in Human Astrocytoma Cells Bearing a Mutated p53 Isoform

  2006cites this paper
• Targeting the EGFR pathway for cancer therapy.

  2006cites this paper
• Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: towards personalized medicine.

  2006cites this paper
• Targeting of solid tumors and blood malignancies by antibody-based therapies — EGFR-pathway as an example

  2006cites this paper
• FILARIAL NEMATODE SECRETED PRODUCT ES‐62 IS AN ANTI‐INFLAMMATORY AGENT: THERAPEUTIC POTENTIAL OF SMALL MOLECULE DERIVATIVES AND ES‐62 PEPTIDE MIMETICS

  2006cites this paper
• The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation

  2006cites this paper
• Cancer-selective therapy of the future: Apoptin and its mechanism of action

  2006cites this paper
• Function and molecular mechanism of tumor-targeted peptides for delivering therapeutic genes and chemical drugs.

  2006cites this paper
• (protein kinase / protein kinase inhibitor / cancer therapy)

  2006cites this paper
• Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells

  2006cites this paper
• Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approach.

  2006cites this paper
• Apoptin ond Its Mechanism of Action

  2006cites this paper
• Protein kinase inhibitors.

  2006cites this paper
• Protein kinases, their function and implication in cancer and other diseases.

  2006influential citation
• Apoptosis in liver diseases--detection and therapeutic applications.

  2005cites this paper
• 308 Peptide-based approaches to treat asthma , arthritis , other autoimmune diseases and pathologies of the central nervous system

  2005cites this paper
• MEKK1-induced apoptosis is mediated by Smac/Diablo release from the mitochondria.

  2005cites this paper
• Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system.

  2005cites this paper
• Current strategies for the development of peptide‐based anti‐cancer therapeutics

  2005cites this paper
• Adenosine and deoxyadenosine induces apoptosis in oestrogen receptor‐positive and ‐negative human breast cancer cells via the intrinsic pathway

  2005cites this paper
• Protein kinases, their function and implication in cancer and other diseases.

  2004cites this paper
• International Journal of Nanomedicine Dovepress Antitumor Activity of Silver Nanoparticles in Dalton's Lymphoma Ascites Tumor Model

  year unknowncites this paper
• Protein Kinase Inhibitors ( protein kinase / protein kinase inhibitor / cancer therapy )

  year unknowncites this paper